Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-98768111 in Advanced Prostate Cancer
NCT07746713Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2026
- Primary completion
- Mar 2029
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of JNJ-98768111 in prostate cancer (PCa), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events and Number of Participants with Dose-Limiting Toxicities. Started Aug 2026; status: recruiting.
02
Drugs
JNJ-98768111
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07746713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07746713.